Last reviewed · How we verify
Decitabine plus Fludarabine and Busulfan — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Decitabine plus Fludarabine and Busulfan (Decitabine plus Fludarabine and Busulfan) — Hackensack Meridian Health.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Decitabine plus Fludarabine and Busulfan TARGET | Decitabine plus Fludarabine and Busulfan | Hackensack Meridian Health | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Decitabine plus Fludarabine and Busulfan CI watch — RSS
- Decitabine plus Fludarabine and Busulfan CI watch — Atom
- Decitabine plus Fludarabine and Busulfan CI watch — JSON
- Decitabine plus Fludarabine and Busulfan alone — RSS
Cite this brief
Drug Landscape (2026). Decitabine plus Fludarabine and Busulfan — Competitive Intelligence Brief. https://druglandscape.com/ci/decitabine-plus-fludarabine-and-busulfan. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab